Cardiometabolic risk and subclinical vascular damage assessment in idiopathic inflammatory myopathies: a challenge for the clinician.
Simone Barsotti(Ospedale Versilia), Maria Aurora Morales(Istituto di Fisiologia Clinica), Chiara Saponaro(University of Pisa), Claudia Ferrari(Ospedale Santa Chiara), Rosaria Talarico(University of Pisa), Melania Gaggini(Istituto di Fisiologia Clinica), Nicole Di Lascio(Istituto di Fisiologia Clinica), Amalia Gastaldelli(National Research Council), Elisabetta Bianchini(Istituto di Fisiologia Clinica), E. Buzzigoli(Istituto di Fisiologia Clinica), R Neri(University of Pisa), Marta Mosca(University of Pisa)
PubMed
December 17, 2019
Cited by 7
Related Papers
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Non-Alcoholic Fatty Liver Disease (NAFLD) and Its Connection with Insulin Resistance, Dyslipidemia, Atherosclerosis and Coronary Heart Disease
|Nutrients|2013|821
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726